Completed PHASE2 INTERVENTIONAL 2-arm NCT03093103

Empagliflozin and Renal Oxygenation in Healthy Volunteers (EMPA-REIN)

Effects of the SGLT2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-diabetic Subjects

Sponsor: Centre Hospitalier Universitaire Vaudois

Interventions Empagliflozin 10 mg Placebo

Updated 7 times since 2017 Last updated: Jul 29, 2019 Started: Mar 16, 2017 Primary completion: Dec 30, 2018 Completion: Dec 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Nephropathy, this trial is completed. The trial is conducted by Centre Hospitalier Universitaire Vaudois and has accumulated 7 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Aug 2019 — Jan 2021 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Jun 2018 — Aug 2019 [monthly]

Recruiting PHASE2

▶ Show 2 earlier versions

Dec 2017 — Jun 2018 [monthly]

Recruiting PHASE2
May 2017 — Dec 2017 [monthly]

Recruiting PHASE2

First recorded

Mar 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centre Hospitalier Universitaire Vaudois

Data source: Centre Hospitalier Universitaire Vaudois

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lausanne, Switzerland